Insider Selling: VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $109,166.43 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 6,533 shares of the stock in a transaction dated Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43. Following the completion of the sale, the insider directly owned 3,552,710 shares in the company, valued at approximately $59,365,784.10. The trade was a 0.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total transaction of $20,260.03.

VanEck Biotech ETF Stock Performance

NASDAQ BBH traded up $2.26 on Thursday, hitting $206.25. The stock had a trading volume of 3,431 shares, compared to its average volume of 6,008. The firm has a 50-day moving average of $192.26 and a 200-day moving average of $191.76. VanEck Biotech ETF has a 52-week low of $154.75 and a 52-week high of $212.54.

Institutional Investors Weigh In On VanEck Biotech ETF

Several large investors have recently added to or reduced their stakes in the business. Segall Bryant & Hamill LLC purchased a new position in VanEck Biotech ETF during the first quarter worth about $881,000. Paragon Private Wealth Management LLC raised its holdings in shares of VanEck Biotech ETF by 5.3% in the 1st quarter. Paragon Private Wealth Management LLC now owns 15,368 shares of the company’s stock valued at $2,890,000 after acquiring an additional 775 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of VanEck Biotech ETF by 44.3% in the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after acquiring an additional 20,375 shares in the last quarter. Royal Bank of Canada boosted its position in shares of VanEck Biotech ETF by 4.3% during the 1st quarter. Royal Bank of Canada now owns 13,843 shares of the company’s stock valued at $2,603,000 after acquiring an additional 565 shares during the last quarter. Finally, Wealthfront Advisers LLC boosted its position in shares of VanEck Biotech ETF by 27.0% during the 1st quarter. Wealthfront Advisers LLC now owns 7,004 shares of the company’s stock valued at $1,317,000 after acquiring an additional 1,491 shares during the last quarter. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.